Top Markets
Coin of the day
Abbott Laboratories Abbott Laboratories

Abbott Laboratories

ABT
Rangering i aksjer #118
Abbott Laboratories, along with its affiliated entities, is a global healthcare... Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
Aksjekurs
$97.46
Sist synkronisert: 2026-10-02
Markedsverdi
$168.63B
Endring (1 dag)
0.77%
Endring (1 år)
-27.59%
Land
US
Handel Abbott Laboratories (ABT)

Kategori

P/E-forhold for Abbott Laboratories (ABT)
P/E-forhold per October 2026 TTM: 31.78
Ifølge Abbott Laboratories sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 31.78. Ved slutten av 2024 hadde selskapet en P/E på 14.62.
P/E-forholdshistorikk for Abbott Laboratories fra 2000 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
2026 (TTM) 31.78 -5.28%
2025 33.55 129.56%
2024 14.62 -56.18%
2023 33.35 20.14%
2022 27.76 -21.42%
2021 35.33 -18.19%
2020 43.19 3.69%
2019 41.65 -22.33%
2018 53.63 -74.29%
2017 208.61 416.25%
2016 40.41 170.24%
2015 14.95 -49.70%
2014 29.72 29.04%
2013 23.04 177.98%
2012 8.29 -7.25%
2011 8.93 16.57%
2010 7.66 10.25%
2009 6.95 -13.90%
2008 8.07 -29.75%
2007 11.49 -44.65%
2006 20.76 139.13%
2005 8.68 -19.34%
2004 10.76 -9.48%
2003 11.89 18.37%
2002 10.05 -59.93%
2001 25.07 107.16%
2000 12.10 0.00%
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
21.39 -32.70%
IE
28.32 -10.90%
US
17.60 -44.61%
US
- -
DE
49.61 56.11%
US
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.